New analysis of Phase II data at AACR assesses ImaginAb’s investigational CD8 ImmunoPET technology’s ability to predict response in immunotherapy

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapies announces a poster presentation at AACR 2023 of an independent analysis undertaken by AstraZeneca, on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study.